NASDAQ:NBTX Nanobiotix - NBTX Stock Forecast, Price & News Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Nanobiotix S.A. Please log in to your account or sign up in order to add this asset to your watchlist. $3.45 0.00 (0.00%) (As of 03/24/2023 12:00 AM ET) Add Compare Share Share Today's Range$3.45▼$3.4550-Day Range$3.45▼$4.4952-Week Range$2.32▼$7.97VolumeN/AAverage Volume1,942 shsMarket Capitalization$120.34 millionP/E RatioN/ADividend YieldN/APrice TargetN/A ProfileAnalyst RatingsChartCompetitorsFinancialsInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media About Nanobiotix (NASDAQ:NBTX) StockNanobiotix S.A., a clinical-stage biotechnology, focuses on developing product candidates for the treatment of cancer. Its lead product candidate is NBTXR3, a sterile aqueous suspension of crystalline hafnium oxide nanoparticles used for the treatment of soft tissue sarcoma, head and neck cancers, liver cancers, prostate cancer, pancreatic cancer, esophageal cancer, rectal cancer, and non-small cell lung cancer. Nanobiotix S.A. has a partnership with LianBio to develop and commercialize NBTXR3 in Greater China, South Korea, Singapore, and Thailand. The company was incorporated in 2003 and is headquartered in Paris, France.Read More Receive NBTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nanobiotix and its competitors with MarketBeat's FREE daily newsletter. Email Address NBTX Stock News HeadlinesMarch 27, 2023 | finance.yahoo.comNanobiotix to Postpone Full Year 2022 Financial Results and Conference CallMarch 27, 2023 | americanbankingnews.comNanobiotix (NBTX) to Release Quarterly Earnings on TuesdayMarch 28, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!March 14, 2023 | finance.yahoo.comNanobiotix to Provide Operational Update and Report Full Year 2022 Financial Results on March 28, 2023December 27, 2022 | msn.comNanobiotix randomizes 1st patient in US in phase 3 head/neck cancer trialDecember 27, 2022 | finance.yahoo.comNANOBIOTIX Announces First Patient Randomized in the United States in Global Phase 3 Pivotal Trial Evaluating Radioenhancer NBTXR3 in Head and Neck CancerDecember 21, 2022 | finance.yahoo.comNANOBIOTIX Announces Termination of Liquidity Contract and Publishes End of Contract StatementDecember 8, 2022 | finance.yahoo.comVoting Rights and Shares Capital of the CompanyMarch 28, 2023 | Behind the Markets (Ad)[BREAKING] New "Living Missile" to Replace Nuclear MissilesCBS News Reports: "It's an entirely new type of weapon." The New York Times Reports: "No existing defense can stop it." And one small company is building them for the Pentagon!November 15, 2022 | finance.yahoo.comNANOBIOTIX to Present at the 5th Annual Evercore ISI HealthCONx ConferenceNovember 14, 2022 | finance.yahoo.comNANOBIOTIX Announces Recommended Phase 2 Dose for NBTXR3 in Pancreatic CancerNovember 10, 2022 | finanznachrichten.deNanobiotix S.A.: NANOBIOTIX Provides Third Quarter 2022 Operational and Financial UpdateNovember 10, 2022 | finance.yahoo.comNanobiotix Posts Updated Data For Radiotherapy-Activated Cancer Therapy In Head & Neck Cancer PatientsNovember 10, 2022 | finance.yahoo.comNANOBIOTIX Reports Updated Phase 1 Anti-PD-1 Combination Data That May Support the Immune Stimulation Potential of Radioenhancer NBTXR3 at the 37th Annual Meeting of the Society for Immunotherapy of CancerNovember 9, 2022 | finance.yahoo.comNANOBIOTIX Provides Third Quarter 2022 Operational and Financial UpdateNovember 8, 2022 | finance.yahoo.comNANOBIOTIX Voting Rights and Shares Capital of the CompanyNovember 2, 2022 | finance.yahoo.comNANOBIOTIX Appoints Renowned Global Experts to Comprehensive Scientific Advisory Board for Potential First-in-Class Radioenhancer NBTXR3November 1, 2022 | finance.yahoo.comNANOBIOTIX to Present at the Jefferies London Healthcare ConferenceOctober 27, 2022 | finance.yahoo.comNANOBIOTIX to Announce Third Quarter 2022 Financial Results on November 9, 2022October 18, 2022 | finance.yahoo.comNANOBIOTIX Executes Definitive Agreement to Restructure Existing Loan With the European Investment BankSeptember 28, 2022 | finance.yahoo.comNanobiotix Provides Business Update and Reports Financial Results for the First Half of 2022September 23, 2022 | finance.yahoo.comNanobiotix to Announce Half Year 2022 Financial Results on September 28, 2022September 22, 2022 | finance.yahoo.comNanobiotix Establishes Recommended Dose For Registrational Study Of Head & Neck Combo Therapy TrialSeptember 21, 2022 | finance.yahoo.comNanobiotix Establishes Recommended Dose for Planned Registrational Study Evaluating NBTXR3 Plus Anti-PD-1 for Patients With Metastatic Head and Neck Cancer Resistant to Prior ImmunotherapySeptember 14, 2022 | seekingalpha.comNanobiotix agrees in principle to restructure debt obligations with EU's investment bankSeptember 12, 2022 | finance.yahoo.comNanobiotix Announces Agreement in Principle to Restructure Existing Loan Agreement With European Investment Bank, Extending Operating Runway Into Q1 2024September 7, 2022 | finance.yahoo.comNANOBIOTIX and LianBio Announce First Patient Enrolled in Asia in Phase 3 NANORAY-312 Trial Evaluating NBTXR3 for the Treatment of Head and Neck CancerSee More Headlines View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart Receive NBTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Nanobiotix and its competitors with MarketBeat's FREE daily newsletter. Email Address NBTX Company Calendar Today3/28/2023Next Earnings (Confirmed)3/28/2023Fiscal Year End12/31/2023Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:NBTX CUSIPN/A CIK1760854 Webwww.nanobiotix.com Phone33-1-40-26-04-70FaxN/AEmployees98Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)N/A Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet IncomeN/A Net MarginsN/A Pretax MarginN/A Return on EquityN/A Return on AssetsN/A Debt Debt-to-Equity RatioN/A Current Ratio1.71 Quick RatioN/A Sales & Book Value Annual Sales$3.13 million Price / Sales38.45 Cash FlowN/A Price / Cash FlowN/A Book Value$0.91 per share Price / Book3.79Miscellaneous Outstanding Shares34,880,000Free Float33,673,000Market Cap$120.34 million OptionableNot Optionable Beta0.14 Key ExecutivesMr. Laurent Levy Ph.D. (Age 49)Co-Founder, Pres of the Exec. Board & CEO Comp: $585.36kMr. Bart Van RhijnCFO & Member of Exec. BoardMs. Anne-Juliette Hermant M.A. (Age 48)Chief People Officer & Member of Exec. Board Comp: $304.33kProf. Para Prasad Ph.D. (Age 77)Co-Founder and Member of Scientific Board Mr. Earl J. Bergey Ph.d. (Age 67)Co-Founder Mr. Alain DostieChief Operating OfficerMs. Kathryn M. McNeil (Age 47)Sr. VP of Investor Relations Mr. Brandon OwensVP of Strategic Marketing & Corp. CommunicationMs. Elsa BorghiHead of Innovation & Drug DiscoveryMs. Sarah GaubertHead of Communication & Public Affairs DepartmentMore ExecutivesKey CompetitorsIncannex HealthcareNASDAQ:IXHLInozyme PharmaNASDAQ:INZYAlaunos TherapeuticsNASDAQ:TCRTGalectin TherapeuticsNASDAQ:GALTAnixa BiosciencesNASDAQ:ANIXView All Competitors NBTX Stock - Frequently Asked Questions How have NBTX shares performed in 2023? Nanobiotix's stock was trading at $3.67 at the beginning of 2023. Since then, NBTX shares have decreased by 6.0% and is now trading at $3.45. View the best growth stocks for 2023 here. When is Nanobiotix's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Tuesday, March 28th 2023. View our NBTX earnings forecast. How can I listen to Nanobiotix's earnings call? Nanobiotix will be holding an earnings conference call on Wednesday, March 29th at 8:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at 201-689-8573. When did Nanobiotix IPO? (NBTX) raised $95 million in an initial public offering on Friday, December 11th 2020. The company issued 6,500,000 shares at a price of $14.69 per share. Jefferies, Evercore ISI, UBS Investment Bank and Gilbert DuPont served as the underwriters for the IPO. What is Nanobiotix's stock symbol? Nanobiotix trades on the NASDAQ under the ticker symbol "NBTX." How do I buy shares of Nanobiotix? Shares of NBTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. Compare Top Brokerages Here. What is Nanobiotix's stock price today? One share of NBTX stock can currently be purchased for approximately $3.45. How much money does Nanobiotix make? Nanobiotix (NASDAQ:NBTX) has a market capitalization of $120.34 million and generates $3.13 million in revenue each year. How can I contact Nanobiotix? The official website for the company is www.nanobiotix.com. The company can be reached via phone at 33-1-40-26-04-70. This page (NASDAQ:NBTX) was last updated on 3/28/2023 by MarketBeat.com Staff Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.